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Abstract
Nonsyndromic cleft lip with or without cleft palate (nsCL/P) is among the most common human birth defects with
multifactorial etiology. Here, we present results from a genome-wide imputation study of nsCL/P in which, after adding repli-
cation cohort data, four novel risk loci for nsCL/P are identified (at chromosomal regions 2p21, 14q22, 15q24 and 19p13). On a
systematic level, we show that the association signals within this high-density dataset are enriched in functionally-relevant
genomic regions that are active in both human neural crest cells (hNCC) and mouse embryonic craniofacial tissue.
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This enrichment is also detectable in hNCC regions primed for later activity. Using GCTA analyses, we suggest that 30% of the
estimated variance in risk for nsCL/P in the European population can be attributed to common variants, with 25.5% contri-
buted to by the 24 risk loci known to date. For each of these, we identify credible SNPs using a Bayesian refinement approach,
with two loci harbouring only one probable causal variant. Finally, we demonstrate that there is no polygenic component of
nsCL/P detectable that is shared with nonsyndromic cleft palate only (nsCPO). Our data suggest that, while common variants
are strongly contributing to risk for nsCL/P, they do not seem to be involved in nsCPO which might be more often caused by
rare deleterious variants. Our study generates novel insights into both nsCL/P and nsCPO etiology and provides a systematic
framework for research into craniofacial development and malformation.
Introduction
Nonsyndromic cleft lip with or without cleft palate (nsCL/P) is
among the most common of all human birth defects (1). The ge-
netic components of the underlying multifactorial etiology have
been investigated extensively, with substantial recent progress
due mainly to advances in large-scale genotyping technologies.
Using genome-wide association studies (GWAS) together with
replication assays, candidate gene and linkage studies, 20 genetic
risk loci have been identified to date (2–11). A substantial fraction
of these loci confer their effects in diverse populations (10–14), al-
though the strength of the associations for single variants in dif-
ferent populations varies as a function of differences in risk allele
frequencies and locus heterogeneity; also reflected by different
prevalence rates for nsCL/P observed in different populations
(1,11,15). Despite these successes it remains unclear how much of
the variance in nsCL/P risk can be explained by the risk loci iden-
tified to date or common genetic variation in general, and the
identification of additional genetic factors contributing to nsCL/P
is to be expected.
In addition, one interesting question is the extent to which
genetic factors overlap between nsCL/P and isolated (nonsyn-
dromic) cleft palate where the lip is unaffected (nsCPO); the sec-
ond most common type of orofacial clefting (OFC), after nsCL/P
(15). There is ongoing discussion as to whether both disorders
represent different OFC subphenotypes with shared genetic fac-
tors or whether they are genetically distinct conditions. The lat-
ter hypothesis is supported by epidemiological studies showing
larger recurrence risks in either of the nsCL/P and nsCPO groups
respectively, with cross-over phenotypes showing recurrence
risks only slightly above the population background rates (16–
18). Moreover, while GWAS have identified numerous associa-
tions reaching genome-wide significance for nsCL/P, it was only
recently the first common variant reaching genome-wide signif-
icance for nsCPO was identified (19,20). Notably, this missense
variant in grainyhead-like 3 (GRHL3 [MIM 608317]) did not show
any association with nsCL/P (19). Despite these observations,
candidate gene approaches have revealed variants nominally
associated with both nsCL/P and nsCPO, the most conclusive
being markers at the FOXE1 locus (8,21), suggesting that some
regions might contribute to both traits with small effect sizes.
However, it has remained unclear whether or not shared poly-
genic components might be involved in risk for both
malformations.
Given the recent advances in sequence and haplotype anno-
tation of numerous human populations by projects such as
1000 Genomes (22) or Genomes of the Netherlands (23), im-
proved imputation and statistical methods as well as increas-
ingly large sample sizes, it has now become possible to generate
and comprehensively analyze high-density imputed datasets
for complex phenotypes including nsCL/P and nsCPO. Such
datasets have the power to identify novel associations that had
escaped prior detection due to insufficient coverage of that
region and/or low linkage disequilibrium (LD) between the
genotyped markers and causal variants. In addition, this ap-
proach harbours enormous potential for the identification of al-
lelic heterogeneity between populations and (sub-)phenotypes,
and overlap with functionally annotated regions. Therefore, in
the present study, we used data from previously published
GWAS datasets for both nsCL/P (2,7) and nsCPO (24) from
European and Asian populations, part of which we obtained
from dbGaP with approved data access, to increase our under-
standing of the genetic architecture. Our results provide sys-
tematic novel insights in both genetic etiology and underlying
biology of both types of facial malformation.
Results
Genome-wide imputation in nsCL/P and meta-analysis
(discovery phase)
We used genotypes from our previously published meta-
analysis of nsCL/P (6) which comprised 399 cases, 1318 controls
(Bonn GWAS cohort (7)) and 1461 case-parent trios (Baltimore
study: 666 European, 795 Asian (2), Supplementary Material, Fig.
S1). After imputation and quality control (QC), 8.01 million
variants were retained in the analysis. The genomic inflation
factor was 1.044 for the analysis of European individuals only
(metaEuro), and 1.047 for the overall analysis including
Europeans and Asians (metaall). Quantile-quantile (QQ)-plots in-
cluding the imputed data were similar when compared to QQ-
plots including genotyped variants only (Supplementary
Material, Fig. S2), indicating the absence of a technical bias
due to the imputation performed. A total of 2556 SNPs showed
P-values of at most 11005 in at least one of the analyses, 2002
of which mapped to 17 of the 20 nsCL/P risk loci that were
known at the time of analysis (no variants mapped to the FOXE1
region and the chromosomal regions 17q23 and 19q13). Of the
remaining 554 variants, two (rs6740960, rs4952552; both at chro-
mosome 2p21) reached Pmeta_Euro< 51008 in the European
analysis, while three additional variants at two loci met this
threshold when Asian samples were included (metaall,
Supplementary Material, Figs. S1 and S3, Table S1). These
variants included two at chromosome 14q22 (rs4901118,
rs60454187) and rs115681412 which maps to the major histo-
compatibility complex (MHC) region at chromosome 6. To ex-
clude imputation errors at the highly variable MHC region (25),
we performed a specific HLA imputation using T1DGC reference
data, yielding P¼ 4.61 1008 for rs115681412 in metaall.
Notably, none of these five variants was present on the 550k/
610k arrays used in the original studies.
The lead SNP at the newly identified risk region at chromo-
some 2p21 (abbreviated as 2p21PKDCC), rs6740960, maps
1.36 Mb away from rs7590268, the lead SNP located within the
THADA gene at the previously identified locus within
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chromosome 2p21 (2p21THADA, (6)). We used conditional analy-
ses in the Bonn case-control GWAS data to show that both ef-
fects are independent from one another: the P-value for
rs6740960 (Puncond.¼ 1.38 1004, Pcond_rs7590268¼3.01 1004)
increased only marginally when conditioned on rs7590268,
and also for rs7590268 (Puncond.¼1.68 1005) when condi-
tioned on rs6749060 (Pcond_rs6740960¼3.62 1005).
Replication and combined analysis
To confirm the findings obtained by imputation and in an at-
tempt to identify further risk loci, 44 SNPs were selected for
replication in an independent case-control cohort of mixed
ethnicities (574 cases, 1635 controls, Supplementary Material,
Fig. S1). Of the 42 SNPs passing QC, five showed P< 0.05
(Supplementary Material, Table S3), including those at chro-
mosomes 2p21PKDCC and 14q22. No additional variant reached
genome-wide significance when replication and imputed data
were combined (Table 1, Supplementary Material, Table S1).
Accounting for potential ethnic-specific factors, we addition-
ally combined metaEuro plus the European part of the replica-
tion cohort (i.e. the Bonn replication sample (n¼ 224 cases/921
controls); Supplementary Material, Table S1 and Fig. S1). In
that analysis a missense variant at chromosome 19p13
(rs3746101; MKNK2, p.Q10K) reached genome-wide signifi-
cance (P¼ 2.44 1008, Table 1). This variant was significantly
associated with nsCL/P in the Central European (Bonn) com-
ponent of the replication sample only (P¼ 0.03) while it did
not show association in either Mexican or Yemeni samples
(P> 0.3, Supplementary Material, Table S1).
The high-density dataset also allowed us to combine results di-
rectly with summary statistics available from other studies on
nsCL/P without the need to use proxy SNPs. We assessed published
data on 227 SNPs from a recent multiethnic study on nsCL/P (11),
and combined these data with the imputed Bonn GWAS data
(meta-analysis of the entire dataset was not possible due to indi-
viduals overlapping between studies (2) and (11)). In the combined
analysis of European individuals (Supplementary Material,
Table S4), no novel associations were detected. In the multiethnic
combination (Supplementary Material, Table S5), we observed
one locus at chromosome 15q24, previously reported as sugges-
tive (11), which reached genome-wide significance (rs28689146,
P¼ 6.61 1009, Table 1, Fig. 1).
Associations with other traits
The present dataset on nsCL/P allows further analysis of related
and/or non-disease traits in silico. For instance, it has been
shown that unaffected family members of patients with nsCL/P
show differences in facial morphometrics such as a broader na-
sal cavity, shorter upper and longer lower faces (27), and seven
genetic loci have been found to be associated with various cra-
niofacial morphometric traits (28–30). Analyzing these variants
in our dataset did not reveal any significant association (P> 0.2,
Supplementary Material, Table S6), nor did any variants at plus/
minus 500 kb withstand correction for multiple testing. We also
searched for yet unknown trait associations with nsCL/P risk re-
gions by assessing the GWAS catalogue (31) using both the
list of credible SNPs and all SNPs in strong linkage disequilib-
rium (i.e. r2>0.8) in the European population. Three SNPs at two
loci were associated with two non-clefting traits, i.e. the FOXE1
locus with thyroid cancer (32), and the chromosome 3p11 locus
with ocular axial length, a quantitative measure for myopia (33)
(Supplementary Material, Table S7). At the FOXE1 locus, the risk
allele of two variants mapping close to a previously identified
craniofacial enhancer hsCNEþ 22.6 (34) showed decreased risk
for thyroid cancer (32). In addition, two common variants lo-
cated within this particular enhancer (rs12342417, rs10984103)
showed association with risk for nsCL/P and are listed among
the credible SNPs (Supplementary Material, Table S8, see next
paragraph).
Identification of credible SNPs
We next aimed at identifying SNPs which are highly probable to
have a causative contribution to nsCL/P, i.e. the “credible SNP”
set, for each of the 24 risk loci reaching genome-wide signifi-
cance in our present study (n¼ 4) and previous research (n¼ 20,
Supplementary Material, Table S9, (2–11)). We herefore used a
Bayesian framework analysis in the metaEuro dataset (Table 2,
Supplementary Material, Table S8). In five of the nsCL/P regions,
including chromosome 8q24, the set of credible SNPs did not en-
compass the genotyped lead SNP identified in the respective
GWAS where these loci were originally identified. For two re-
gions, at chromosomes 2p21PKDCC and 17q13, only one SNP had
a posterior probability of 95%, suggesting these were causative
in the European population.
Table 1. Association results for novel nsCL/P risk loci detected by imputation and replication
Locus Lead SNPa Chromosomal
position
Allelesb GWAS_imputed P_Replication Combined analysis
P_metaEuro P_metaall Pcomb_Euro Pcomb_All
(a) Loci identified with genome-wide significance by imputation and replication
2p21 rs6740960 42181679 T/A 3.29E-09 1.68E-09 3.32E-04 1.86E-10 5.71E-13
14q22 rs4901118 51856109 A/G 7.51E-07 5.44E-09 2.56E-02 2.00E-07 6.94E-10
19p13 rs3746101 2050823 T/G 2.30E-07 4.52E-04 3.17E-02 c 2.44E-08 8.32E-05
(b) Loci identified with genome-wide significance by combining imputed Bonn GWAS dataset and (11) summary statistics
15q24 rs28689146 75005575 A/T 6.54E-03 (3.6E-02)d 2.35E-02 5.4E-08e n.a.f 6.61E-09
aDefined as lowest P-value in genome-wide imputation.
bRisk allele in bold.
cP-value for Bonn replication cohort only.
dNumber in brackets indicates P-value for rs28689146 in Bonn GWAS case-control cohort. This cohort was used for in silico combination with replication cohort of
Leslie et al. (2016) as there were overlapping individuals between Leslie et al. (11) and Beaty et al. (2).
eP-value from Leslie et al. 2016 (11).
fNo summary statistics for rs28689146 in Leslie et al. (11) for the European dataset.
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Insights into nsCL/P biology by annotating risk loci
To gain insights into the biology of nsCL/P, we next performed
in-depth analyses of the 24 recognized risk loci. These
approaches included DEPICT analyses to identify enriched gene
sets and pathways, as well as conditional analyses to investi-
gate potential secondary effects.
To identify tissues in which genes near all 24 nsCL/P
associated SNPs are highly expressed, and gene sets showing
significant enrichment among these risk loci, we used DEPICT
(35) in two settings; (i) including the 24 risk loci (Supplementary
Material, Tables S10 and S11), and (ii) all autosomal SNPs with
P< 1005 in metaEuro (Supplementary Material, Tables S10 and
S11). In the tissue enrichment analysis, strong results were ob-
served for tissues related to the stomatognathic system. The re-
sult for the MEsH term "dentition" met the false discovery rate
(FDR) threshold. At the pathway level, our analysis did not iden-
tify any significantly enriched gene set that survived correction
for multiple testing (at FDR< 0.05).
We also investigated potential secondary effects at each of
the 24 risk loci, by performing conditional analyses on the re-
spective lead SNP (i.e. the SNP with the lowest P-value except
for the regions at chromosomes 2p21PKDCC and 17q13 where the
Figure 1. Regional association plots of four novel risk loci. Using genome-wide imputed data, in vitro and in silico replications, four novel risk loci for nsCL/P were identi-
fied. Plotted SNPs include both genotyped and imputed variants, respectively. (A) Two regions on chromosomes 2p21 and 14q22 reached genome-wide significance in
the imputation analysis of metaall and further decreased in P-values when replication data from a mixed ethnicity case-control cohort were added. (B) Analysis of
metaEuro and the European replication cohort revealed genome-wide significance for a region on chromosome 19p13. (C) In silico replication of previously suggestive
findings at chromosome 15q24 (11) using the metaall data revealed genome-wide significance for rs28689146. A second variant (rs11072496, bottom panel) fails to reach
this threshold but improves capture of the haplotype structure. Plots were generated using LocusZoom (26).
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credible SNP with 95% posterior probability was chosen) using
the imputed data from the Bonn GWAS cohort. This approach
identified 64 SNPs with Pcond<10
03 and a lower P-value in the
conditional analysis as compared to the un-conditioned situa-
tion (Supplementary Material, Table S14). The majority of these
SNPs mapped to five of the 24 chromosomal risk loci (1p36,
2p24, 13q31, 17p13 and 19q13, Supplementary Material, Fig. S4).
Co-localization of association signals in relevant
regulatory regions
In contrast to many common phenotypes for which human
material is available and has been used by projects such
as Epigenomics Roadmap (36), follow-up analyses of genetic
findings for nsCL/P are hampered by the early embryonic time-
point of facial development where defects occur; and the lack of
appropriate human tissue. We therefore annotated the high-
density nsCL/P dataset with ChIP-seq data previously generated
to map active enhancers in human neural crest cells (hNCC,
(37)) and active promoters and enhancers in mouse craniofacial
embryonic tissue (38). Since hNCC are the precursors of the
mesenchymal progenitors that will go on to generate most of
the facial cartilage and bone during craniofacial development,
we hypothesized the previously generated ChIP-seq datasets in
hNCC (i.e. p300, H3K4me1, H3K27ac and TFAP2A) could be re-
analyzed to define a broader set of cis-regulatory elements, in-
cluding primed enhancers (see Methods). To identify whether
nsCL/P association signals from the genome-wide dataset
are significantly overrepresented within regulatory regions
considered active during craniofacial development, we per-
formed co-localization analyses (Table 3). Similar cis-regulatory
maps generated from mouse embryonic limbs (39) and IRF6
binding sites identified in human adult keratinocytes (40) were
used as controls. We identified highly significant enrichments
in hNCC when either active enhancers alone or a broader set of
active and primed enhancers were considered. Similarly, signifi-
cant overrepresentations were also seen with mouse craniofa-
cial enhancers (Table 3). Lower levels of significance were
observed with mouse craniofacial promoter regions, while no
enrichment was found in the control datasets of mouse limb-
tissue and human adult keratinocytes.
Estimation of variance explained in nsCL/P
We estimated the heritability explained by common variants in
the imputed Bonn GWAS dataset using the software GCTA (41).
In addition, we estimated the proportion of variance in risk for
nsCL/P that can be attributed to the recognized 24 risk loci using
logistic regression. We found that 32.1% (8.5% standard error) of
variance in the GWAS data can be attributed to common risk
factors, with 25.5% contributed by these 24 risk regions. We also
determined to what extent a polygenic component contributes
to nsCL/P. We generated score alleles in the Bonn case-control
GWAS cohort (discovery sample) and tested them for enrich-
ment in the nsCL/P target sample (i.e. Baltimore trio cohort of
European descent). We observed a highly significant enrich-
ment of score alleles at a variety of P-value thresholds
(Supplementary Material, Table S15A), with the lowest P-value
in the Wald test (PWald) being obtained for the unpruned
matched SNP set at PT< 0.2 (PcWald¼ 2.04 1011) with an esti-
mated R2 of 9.7% (Fig. 2). The amount of explained variance was
observed to be slightly higher for the unpruned dataset as com-
pared to the pruned dataset (maximum R2¼6.8%).Ta
b
le
3.
C
o
-l
o
ca
li
za
ti
o
n
an
al
ys
es
o
f
n
sC
L/
P
im
p
u
ta
ti
o
n
an
al
ys
es
re
su
lt
s
in
au
to
so
m
al
re
gi
o
n
s
o
f
fu
n
ct
io
n
al
ly
an
n
o
ta
te
d
d
at
as
et
s
St
u
d
y
n
am
e
A
n
n
o
ta
ti
o
n
N
u
m
be
r
re
gi
o
n
s
N
u
m
be
r
SN
Ps
En
ri
ch
m
en
t
m
et
a E
u
ro
a
En
ri
ch
m
en
t
m
et
a a
ll
R
ef
er
en
ce
s
P
gr
o
u
p
s
P
n
o
m
in
al
P
gr
o
u
p
s
P
n
o
m
in
al
N
eu
ra
lc
re
st
ce
ll
li
n
e
(N
C
C
)
A
ct
iv
e
en
h
an
ce
r
42
93
68
86
<
0.
00
01
0.
04
73
<
0.
00
01
<
0.
00
01
R
ad
a-
Ig
le
si
as
et
al
.(
37
)
M
o
u
se
cr
an
io
fa
ci
al
ti
ss
u
e
E1
1.
5
(M
C
T
_P
)
A
ct
iv
e
p
ro
m
o
te
r
42
50
15
29
7
0.
00
2
0.
03
0.
00
01
0.
04
1
A
tt
an
as
io
et
al
.(
38
)
M
o
u
se
cr
an
io
fa
ci
al
ti
ss
u
e
E1
1.
5
(M
C
T
_E
)
A
ct
iv
e
en
h
an
ce
r
70
68
24
74
3
0.
00
02
0.
00
02
<
0.
00
01
0.
00
4
A
tt
an
as
io
et
al
.(
38
)
N
eu
ra
lc
re
st
ce
ll
li
n
e
(A
ct
iv
e
an
d
p
ri
m
ed
C
R
M
s)
A
ct
iv
e
an
d
p
ri
m
ed
en
h
an
ce
rs
22
79
2
18
0
81
0
<
0.
00
01
<
0.
00
01
<
0.
00
01
<
0.
00
01
D
at
a
fr
o
m
R
ad
a-
Ig
le
si
as
et
al
.
(3
7)
re
an
al
yz
ed
N
eu
ra
lc
re
st
ce
ll
li
n
e
(A
ct
iv
e
C
R
M
s)
A
ct
iv
e
en
h
an
ce
rs
16
17
7
14
1
23
1
<
0.
00
01
<
0.
00
01
<
0.
00
01
<
0.
00
01
D
at
a
fr
o
m
R
ad
a-
Ig
le
si
as
et
al
.
(3
7)
re
an
al
yz
ed
M
o
u
se
li
m
b
ti
ss
u
e
E1
1.
5
(C
O
N
1)
A
ct
iv
e
en
h
an
ce
r
20
30
37
13
0.
10
0.
18
0.
30
0.
35
V
is
el
et
al
.(
39
)
IR
F6
bi
n
d
in
g
si
te
s
in
ke
ra
ti
n
o
cy
te
s
(C
O
N
2)
IR
F6
bi
n
d
in
g
si
te
s
38
93
12
19
0.
6
0.
26
0.
00
5
0.
19
B
o
tt
ie
t
al
.(
40
)
C
O
N
—
co
n
tr
o
ld
at
as
et
s,
C
R
M
—
ci
s-
re
gu
la
to
ry
m
o
d
u
le
.
a
P-
va
lu
es
o
n
e-
si
d
ed
;i
ta
lic
s
if
si
gn
ifi
ca
n
t
af
te
r
co
rr
ec
ti
o
n
fo
r
m
u
lt
ip
le
te
st
in
g
(P
<
0.
00
15
6)
.
834 | Human Molecular Genetics, 2017, Vol. 26, No. 4
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/26/4/829/2901818 by U
niversidad  Autónom
a de N
uevo León user on 13 M
arch 2019
Insights into the genetic etiology of nsCL/P and nsCPO
To investigate the potential etiological overlap between nsCL/P
and nsCPO, we generated and analyzed imputed data from a
previous genome-wide nsCPO study that included 550 nsCPO
trios ((24), see Methods). No variant reached the threshold
of genome-wide significance in either the European or in the
analysis of mixed ethnicities (Supplementary Material, Figs. S5
and S6). The only genome-wide significant risk locus for nsCPO
identified so far (19, 20) had PnsCPO¼1.18 1004.
The lead SNPs and associated regions of the 24 recognized
nsCL/P risk loci were analyzed in the nsCPO dataset
(Supplementary Material, Table S16). At lead SNP level, only
rs3758249 at the FOXE1 locus showed significant associations in
nsCPO after correction for multiple testing (PnsCPO_all¼1.84 1003),
which confirmed prior findings on associations with both traits
(8,21). This finding was supported by additional variants being
strongly associated at this locus (Supplementary Material, Fig. S7).
Three other nsCL/P lead variants (at chromosomes 15q22, 16p13
and 17q22) were significant at the nominal level (Supplementary
Material, Table S16). To investigate allelic or haplotype heterogene-
ity between both traits, the 24 nsCL/P loci (defined as nsCL/P lead
SNP6 500 kb) were extracted from the nsCPO data, revealing 73 078
SNPs passing QC. Fourteen variants had P-values lower than 1004
in the overall analysis (Supplementary Material, Table S17), eight of
which mapped to the 2p21 (THADA) region previously identified (6).
The lowest P-value was observed for rs12476091 (PnsCPO_all¼8.
55 1007) which approaches the threshold of significance (conser-
vative Bonferroni correction for number of SNPs, i.e. 6.84 1007).
Comparison of the regional association plots revealed two distinct
association clusters for nsCPO and nsCL/P. Interestingly, condi-
tional analyses in nsCL/P revealed suggestive association for vari-
ants overlapping the nsCPO-associated region as secondary effect
(Supplementary Material, Fig. S8).
To address a polygenic contribution between nsCL/P and
nsCPO, we finally sought to systematically analyze (1) the joint
contribution of the 24 recognized risk loci, and (2) a general
polygenic risk score from nsCL/P applied to nsCPO, using
genome-wide data. For the first approach we generated dosage
values for transmitted alleles and non-transmitted alleles in
each of the nsCPO trios, for each of the 24 nsCL/P lead SNPs
(Supplementary Material, Table S8). In each trio, both dosages
were weighted with the logarithmic relative risks (RR) of the
nsCL/P risk allele and summed over all 24 lead SNPs. This ap-
proach resulted in a transmitted and non-transmitted score
for each nsCPO trio. Subtracting the non-transmitted score
from the transmitted score revealed a mean over families of
0.135161.51, indicating that in aggregate, these 24 recog-
nized lead SNPs for nsCL/P do not contribute to nsCPO risk.
The difference from a mean of 0 was not significant (P¼ 0.195).
For the second approach, we used the polygenic score
generated in the nsCL/P discovery dataset and evaluated its
association in the nsCPO dataset of European ancestry trios
(Supplementary Material, Table S15B). In none of the settings
(pruned, unpruned, matched and non-matched) was a signif-
icant enrichment of nsCL/P risk allele scores in nsCPO de-
tected (P> 0.1, Supplementary Material, Table S15, Fig. 2).
Discussion
In the first wave of GWAS, analysis of common variants was
limited to a subset of 500 000 variants present on commer-
cially available microarrays. Although these variants had been
selected to tag the majority of genetic variation, it has become
evident that true associations can be missed in situations where
risk variants had a minor allele frequency lower than 5%; were
not adequately tagged by the genotyped variants; or failed geno-
typing for technical reasons. With advances in the fields of high
marker-density population reference sets and bioinformatic
techniques, accurate prediction of non-genotyped variants has
enabled further discoveries of the genetics underlying complex
disorders (42–44).
Here, we performed large-scale imputation analyses of pre-
viously published GWAS datasets on nsCL/P and nsCPO, two of
the most common types of congenital craniofacial anomalies,
Figure 2. Polygenic risk score analysis in nsCL/P and nsCPO. The amount of variance explained in the target samples based on the polygenic score derived from the
Bonn case-control GWAS nsCL/P discovery sample: (A) for the nsCL/P European trio sample; (B) for the nsCPO European trio sample. The amount of variance explained,
denoted as Nagelkerke’s pseudo R2, is shown on the y-axis. Different association test P-value thresholds (PT) in the discovery dataset are represented by different
colours. Results are shown for both pruned and unpruned analyses, respectively.
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to detect novel risk loci. We identified common variants at four
new loci as risk factors for nsCL/P, while none was identified for
nsCPO. The associations at the chromosomal regions 2p21PKDCC,
14q22 and 19p13 were replicated by genotyping in independent
samples and are therefore deemed as associated with ‘high con-
fidence’, while chromosome 15q24 revealed genome-wide sig-
nificance upon in silico combination of two GWAS datasets.
Notably, one variant in the highly variable MHC region identi-
fied with genome-wide significance in the nsCL/P genome-wide
dataset did not replicate in any of our replication samples, sug-
gesting a false-positive result similar to previous findings (11).
As with most of the previous GWAS hits in nsCL/P and other
complex traits, the top associated variants at chromosomes
2p21PKDCC and 14q22 map in non-coding regions, and might
therefore represent regulatory mutations affecting adjacent
genes. Among the candidate genes at these loci are the protein
kinase domain containing, cytoplasmic gene, (PKDCC [MIM
614150]), whose orthologues are involved in facial development
in both mice (45) and zebrafish (46), FERM-domain containing
6 (FMRD6 [MIM 614555]) and thioredoxin-related transmem-
brane protein 1 (TMX1 [MIM 610527]). In contrast, the top-
associated variant at chromosome 19p13 is a missense variant
in MAP Kinase Interacting Serine/Threonine Kinase 2 (MKNK2
[MIM 605069]). Although modelling MKNK2 protein structure us-
ing Phyre2 (47) revealed considerable changes in protein folding
(Supplementary Material, Fig. S9), functional annotation using
the Variant Effect Predictor (VEP), as well as a low CADD-Phred
score (2.72) suggest rs3746101 may be a benign polymorphism.
These observations suggest the biological effect in cleft patho-
genesis might also result from mis-regulation of either MKNK2
or, more likely, any of the numerous adjacent genes. In the lat-
ter case, candidates at the chromosome 19p13 locus would be
BTB domain containing (BTBD2 [MIM 608531]) which has been
suggested to be involved in early zebrafish development (48), or
casein kinase gamma 2 (CSNK1G2 [MIM 602214]) which is in-
volved in Wnt/beta-catenin signaling during anterio-posterior
patterning (49).
Our study increases the total number of conclusive common
risk factors for nsCL/P to 24, and using credible SNP analyses in
the comprehensive European data suggest likely causative SNPs
at each of these loci. Notably, our results suggest rs6740960
(2p21PKDCC) and rs1880646 (17q13) as likely causative SNPs in
European populations. For other regions, such as those at chro-
mosomes 17q22 (NOG) and 1q32 (IRF6), the credible SNP set con-
tained fewer than 20 variants but included SNPs such as
rs227727 or rs642961, which have been previously shown to
have some functional effect (9,50). It remains unclear whether
the same credible SNP sets would be identified in non-European
populations; therefore, analyses of other distinct genome-wide
datasets (e.g. studies (10) or (11)) would be required. Such an ap-
proach would also be helpful to delineate causal variants at
other loci such as the EPHA3-locus (chromosome 3p11,> 50
SNPs in credible SNP set) using distinct LD patterns in other
populations.
We next sought to analyze whether risk alleles of nsCL/P
in aggregate contribute to risk for nsCPO. The lack of large
etiological overlap between these disorders has been sug-
gested by epidemiological studies, and we now support this
hypothesis by a polygenic score approach based on actual
GWAS data. Interestingly, during preparation of this manu-
script, Wen & Lu developed a novel statistical method to ac-
count for phenotypic heterogeneity between disease subtypes
and, when applying it to nsOFC datasets, confirmed that nsCL/
P and nsCPO have different genetic etiologies (51). While there
is ample evidence for nsCL/P being a multifactorial trait, the
situation remains less clear for nsCPO. It is possible that
nsCPO results from common risk loci which have not yet been
detected (maybe due to low effect sizes and/or inadequate
sample numbers). Alternatively, there is also a strong possibil-
ity that some patients with nsCPO might, in fact, be syn-
dromic cases lacking the usual accompanying signs/
symptoms. In this context, we have recently identified trun-
cating mutations in GRHL3, a gene underlying the autosomal
dominant Van der Woude syndrome (VWS [MIM 119300], (52)),
in four patients with apparent nsCPO (19).
On aggregate, these observations suggest that nsCPO is likely
more often caused by rare or low-frequency variants, while
nsCL/P seems to follow the pattern of complex traits in which
numerous common variants in non-coding regions are associ-
ated with moderate effect sizes. We suggest about one-third of
the variance in risk for nsCL/P can be explained by common var-
iants in general, with one-quarter attributable to the 24 risk loci
currently recognized. These findings suggest that further com-
mon variants are present in the nsCL/P dataset and will have to
be identified by increasing sample sizes, clinical details and/or
approaches to reduce the burden of multiple testing. Also, con-
tributions of rare variants with modest to strong effect sizes, or
gene-environment interactions will probably help to explain the
remaining missing heritability. Based on this, subsequent
analyses of the biological impact of common variants were per-
formed for nsCL/P only.
Notably, using our dataset we were able to identify potential
shared etiologies of nsCL/P. While association with hypothy-
roidism has been established at the FOXE1 locus, the co-
association of variants with myopia and clefting is a novel ob-
servation suggesting shared etiologies. Co-incidence of clefting
defects and eye malformations has been reported previously,
for instance in Stickler syndrome (53) and anophtalmia (54).
Interestingly, the risk allele for nsCL/P decreases axial length,
indicating that a delayed cell growth or disturbed cell migration
might be an underlying shared biological trait of these malfor-
mations. Our attempt to replicate single variants identified in
craniofacial morphometric studies did not prove successful,
however it remains possible that SNPs associated with craniofa-
cial anomalies might contribute in aggregate to nsCL/P risk.
Along these lines, recent analysis of a combined score of nsCL/P
SNPs tested for facial traits revealed association for nose-width-
related measurements, although with little variance explained
(30). This suggests that polygenic risk scores might be helpful
for determining whether these two distinct clinical entities
share some genetic background.
Despite the advances in our understanding of nsCL/P
etiology resulting from published GWAS and the current study,
a number of limitations should be considered. First, our study
did not have sufficient power to identify very low-frequency or
rare variants with confidence; this limits its application with re-
spect to following up causative variants suggested by functional
or candidate gene studies which are in these frequency ranges.
For example, rs138557689 at the FZD6 gene locus was recently
shown to be a functionally-relevant variant in an African-
American family (55). In our dataset, this variant was excluded
due to its low frequency (<1%). Future imputation studies using
combined reference panels such the Haplotype Reference
Consortium will increase the accuracy and informativity of
low frequency variants and provide the opportunity to iden-
tify causal variants in this frequency range for nsCL/P similar
to recent successes in other traits such as bone mineral
density (56).
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One important unanswered question is the exact functional
mechanisms by which the risk alleles contribute to risk of cleft-
ing. The most likely scenario is that associated variants reside in
cis-regulatory modules (CRM) that control expression of their tar-
get genes in a tissue- and time-specific manner. Therefore, the
comprehensive annotation of CRMs in tissues contributing to cra-
niofacial and palate development using, for example, epigenomic
approaches, would be highly desirable. Considering the moderate
sequence conservation of many regulatory elements, CRM maps
should be ideally generated in relevant human tissue, which is a
major hurdle given the early developmental time-points at which
relevant craniofacial tissue should be collected. Alternatively,
CRM maps can be generated in human cell types relevant for cra-
niofacial development (e.g. neural crest), which can be derived in
large amounts from human embryonic stem cells (hESC) using in
vitro differentiation protocols. Moreover, relevant in vivo material
can be isolated from embryonic animal models. Chiefly, our ap-
proach of co-localizing strongly associated variants from the
nsCL/P GWAS with available CRM maps from murine embryonic
craniofacial tissues and hNCC, shows that associated variants are
significantly more often located within regions with regulatory
potential (e.g. enhancers) than expected by chance. Notably, this
enrichment was not observed when control datasets were con-
sidered, illustrating the importance of using CRM maps from rele-
vant tissues and developmental stages. Using previously
generated epigenomic datasets in hNCC, we defined a broad set
of CRMs which included enhancers predicted to display a primed
state that precedes and probably facilitates the future activation
of these enhancers and their target genes (57,58). Interestingly,
this broad CRM map was highly enriched in nsCL/P association
signals, suggesting genetic variation might lead to epigenetic al-
terations at relevant CRMs very early during human embryogene-
sis, which could then affect the regulatory networks controlling
craniofacial development at later prenatal stages. Elucidating if
these early epigenetic alterations actually take place and under-
standing their mechanistic basis might uncover novel causal re-
lationships which are not yet fully understood. To overcome the
limitations associated with the tissues and developmental stage
specificity of CRMs, further cell types and tissues should be func-
tionally annotated, which could certainly span the number of
causative variants that can be identified and molecularly
characterized.
In conclusion, our study generates novel insights into the
etiology of nonsyndromic orofacial clefting by revealing novel
common variants and biological information for nsCL/P and
demonstrating its distinct genetic background from nsCPO.
Based on this, further work will now focus on identifying the
biological mechanisms by which the associated common vari-
ants interfere with normal craniofacial development. Joint con-
sortia efforts such as FaceBase (59) and the development of
novel technologies such as massively parallel regulatory assays
(60, 61) might provide tremendous resources and opportunities
in that direction.
Materials and Methods
Genome-wide imputation (including HLA) plus
meta-analysis (discovery phase)
In 2012, our group performed the first meta-analysis on nsCL/P
using an in-house case-control dataset (Bonn GWAS dataset (7))
and a trio dataset (Baltimore study (2), Supplementary Material,
Fig. S1). Three-hundred-ninety-nine cases, 1318 controls and
1461 individuals had been included, and 497 084 observed SNPs
were analyzed (6). In the present study, these genotype data
from both case-control and trio cohorts were imputed using
IMPUTE2 (62), using 1092 individuals from the 1000 genomes
project (22) as reference panel. For statistical analysis in the
case-control cohort, logistic regression was performed (with
SNPTEST and -method expected (63)), by incorporating the first
five dimensions of the multi-dimensional-scaling coordinates.
For the trio data retrieved from dbGaP (2), a previously pub-
lished method was used (FBATdosage (64)). P-values were sub-
sequently combined using Z-scores, in two approaches:
European individuals only (metaEuro), and European plus Asian
individuals (metaall). Analysis of Asian data only was not cov-
ered by the dbGaP request. To account for the limited power of
imputation approaches to correctly predict rare and low-
frequency variants, we only retained in the analysis SNPs with a
SNPTEST info_score> 0.4 in any of the two datasets (i.e. case-
control/trio) and a minor allele frequency (MAF)> 1% in the con-
trols and non-transmitting parental alleles.
For the MHC region, a HLA-specific imputation was per-
formed. SNP2HLA (65) was used to impute SNPs, amino acid
residues, indels, and two- and four-digit classical alleles for
eight HLA genes in the MHC region from 29 to 33 Mb on chromo-
some 6p21.3. We used the reference panel provided by T1DGC,
which included 5225 European samples with classical typing for
eight HLA genes (66).
nsCL/P replication study (replication phase and
combined analysis)
The replication sample consisted of 610 nsCL/P cases and 1737
controls from three different cohorts (Bonn, Yemen, Mexico,
Supplementary Material, Fig. S1). The same sample was pre-
viously used in an independent study, please refer to (5) for
sample description. Forty-four SNPs were included in the repli-
cation assay. Genotyping was performed using Maldi-ToF on an
in-house Agena Bioscience Sequenom platform. Two SNPs
failed genotyping (rs6030889, rs3091552) and were excluded,
leaving 42 SNPs in the analysis (Supplementary Material, Table
S1). After genotyping, 138 individuals (36 cases, 102 controls)
had to be excluded due to call rates <95%. Final sample num-
bers were: 224 cases/921 controls (Bonn), 152 cases/323 controls
(Mexico) and 198 cases/391 controls (Yemen).
Association statistics were calculated by applying the
Armitage-trend test, for each sample cohort separately. For
each SNP, relative risks of the three replication cohorts were
combined using fixed-effect meta-analysis. For the combination
of these datasets with the imputed data of metaEuro and metaall,
Z-score based analyses were used.
In silico replication: combination with Leslie et al. (2016)
(11) using summary statistics
In a recent multiethnic GWAS, three novel risk loci for nsCL/P
were identified (11). As there was considerable overlap between
individuals (n¼ 317) used in this study (11) and those used in the
Baltimore study (2) (i.e. which were part of the meta-analysis (6)),
results of this study could not be added to the imputed meta-
analysis. In an attempt to combine independent samples, we
therefore combined the Bonn-case-control cohort with (a) data
from the European analysis of (11), and (b) data from the multi-
ethnic cohort of (11). Summary statistics (P-values, risk allele, rel-
ative risks and confidence intervals) were extracted from Table 1,
Supplementary Tables S4 and S5 (11) and combined with imputed
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Bonn GWAS data generated herein. SNPs comprised either im-
puted SNPs with P< 1007 or genotyped SNPs that had yielded
P< 1005 in (11). In the European dataset (comprising 406 trios,
170 cases and 835 controls), 102 SNPs met these quality criteria,
86 of which were also represented in the imputed dataset of the
Bonn GWAS cohort. In the multiethnic cohort (comprising 1319
trios, 823 cases and 1700 controls), 238 variants were identified at
these P-value thresholds, 227 of which were also present in the
Bonn GWAS data. These data were combined using fixed-effect
meta-analysis.
Genome-wide imputation of nsCPO data set
Genotypes for 550 parent-child trios with nsCPO were retrieved
from a previous genome-wide nsCPO study (24). Similar to
nsCL/P, variants were imputed using 1000 genomes as reference
panel, and statistical analysis was performed using FBATdosage
(64) for about 8.38 million variants (info scores0.4, MAF 1% in
the non-transmitting parental alleles). Again, analysis was split
into an European analysis only (CPOEuro), and an analysis of
mixed ethnicities (CPOall).
Polygenic score analysis
We performed polygenic score analysis (a) to analyze whether a
polygenic component contributes to the genetic susceptibility
of nsCL/P, and (b) to determine whether this polygenic compo-
nent of nsCL/P contributes to risk for nsCPO. Based on (67), the
polygenic score analysis was performed using the imputed
Bonn GWAS data as the discovery cohort and two target co-
horts, i.e., European nsCL/P trios from the Baltimore study (2)
for analysis (a) as well as European nsCPO trios (24) for (b). We
used SNPs with MAF 1% in the Bonn GWAS data and info-
scores0.8 in each of the target cohorts.
We generated 11 SNP sets using different thresholds from
the association test P-value (PT) in the discovery sample. For
each SNP set and each individual, a score in the target sample
was calculated as the number of risk alleles which were
weighted using the log relative risks obtained from the disco-
very sample. The polygenic score analysis was performed for all
SNPs and also after pruning on linkage disequilibrium. The lat-
ter approach enabled analysis of a collective contribution of in-
dependent risk alleles (r2<0.25). These polygenic scores were
tested to determine their association with disease status using
logistic regression (unmatched) and conditional logistic regres-
sion (matched) which accounts for correlation status between
cases and pseudo-controls. Nagelkerke’s pseudo R2 was used to
estimate the proportion of the variance of risk to disease in (a)
nsCL/P-trios and (b) nsCPO-trios explained by the polygenic risk
score. The Wald test was used to test for the effect of the poly-
genic score on risk for nsCL/P and nsCPO.
Co-localization analysis
The tissue-specific mode of action of regulatory elements and
the very narrow developmental time range of cleft development
(during 6th to 8th week post-conception) suggest that causative
variants in nsCL/P could be identified by overlapping high-
density genetic datasets with epigenetic datasets from relevant
embryonic tissue or cell types. Given the limitations associated
with embryonic tissue datasets from humans, we used publicly
available datasets for both human neural crest cells (hNCC, (37))
and mouse facial tissue (38). In these datasets, active enhancer
and promoters were identified based on different combinations
of epigenetic marks. Moreover, we re-analyzed the ChIP-seq
datasets previously generated in hNCC (37) to define broader
sets of CRMs in which promoter regions were not explicitly ex-
cluded. These additional CRMs were expected to include primed
enhancers that are inactive but pre-marked in hNCC and which
might become active later in hNCC development, for example
when differentiating into craniofacial mesenchyme. To define
these larger CRM maps, hNCC ChIP-seq datasets were first re-
analyzed with MACS2 (68) using the following criteria:
• p300 and TFAP2A peaks were identified using q  104.
• H3K4me1: peaks were identified using broad settings and q 
104.
• H3K27ac: peaks were identified using broad settings and q 
106.
Next, these peaks were analyzed in a combinatorial manner
to define two sets of CRMs:
• Active CRMs (16 177 regions): regions bound by p300 or
TFAP2A and enriched in H3K27ac within 1Kb.
• Active and Primed CRMs (22 792 regions): it included the Active
CRMs defined above, plus regions enriched in both H3K27ac
and H3K4me1.
In addition, two control cohorts containing similar datasets
generated from mouse embryonic limbs (39) and IRF6 binding
sites identified in human adult keratinocytes (40) were used.
For the co-localization analysis, two different categorization
schemes for P-values were applied. The first scheme (P groups)
consisted of the nine categories 10kþ 1P> 10k for k¼ 1, . . ., 8
and 108 P. The second schema (P nominal) only distin-
guished between P> 0.05 and P 0.05. For both schemes, the fre-
quencies of SNPs being located within and outside annotated
regions were counted within each category. The one-sided ver-
sion of the Cochran-Armitage test for trend was applied to test
for an enrichment of smaller P-values within annotated regions
on the basis of the resulting 92 or 22 contingency table.
Statistical refinement of genetic associations at 24 loci
A Bayesian refinement method was applied at each of the recog-
nized risk loci to determine the subset of most informative SNPs,
referred to as the credible SNP set (69). This approach has pre-
viously been demonstrated to be more efficient at selecting puta-
tively functional SNPs compared to linkage disequilibrium based
approaches (70,71). A genomic interval around each index SNP
was defined by a genetic distance of 0.1 centimorgans (cM) up-
stream and downstream of each index SNP using HapMap fine-
scale recombination rate estimates. An assumption of the
Bayesian refinement method is that each locus contains a single
association, therefore each interval was tested for multiple inde-
pendent associations by including the index SNP as a covariate in
the logistic regression and repeating the analysis conditional on
this SNP. Where multiple associations exist the credible SNP set
was calculated for one SNP while fixing the effect of the other by
including it as a covariate in the logistic regression. To calculate
the credible SNP set for each independent effect the posterior
probability that any particular SNP is the casual SNP was calcu-
lated based on the Bayes factor for the SNP as a proportion of the
mean Bayes factor for all SNPs in the genomic interval. Posterior
probabilities were aggregated to define the smallest set of SNPs
with a total posterior probability of 95% and 99% (69).
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Estimation of variance explained
The GCTA (41) analysis of the explained variance in nsCL/P
risk was performed using the imputed data of the Bonn case-
control GWAS dataset. As GCTA requires genotypes as input,
individual genotypes were called using a threshold of 90%.
The resulting dataset was filtered by keeping SNPs with geno-
type call rates 95%, MAF 1%, HWE P-value1006 and non-
significant differences in missingness between cases and
controls (PLINK (72) P-value 0.05). In total, 5.61 million SNPs,
both genotyped and imputed, respectively, remained after this
quality control of the dataset. Using GCTA and a relationship
cutoff of 5% estimated from the genome-wide markers, we ob-
tained the Genetic Relationship Matrix (GRM) for 1711 individ-
uals (i.e. 399 cases and 1318 controls). The same first five
dimensions of the multi-dimensional-scaling coordinates as
for the association analysis were included in the estimation of
the explained variance by GCTA. A disease prevalence of 0.1%
was assumed.
DEPICT
We applied DEPICT (35) to systematically analyze most likely
causal genes at the given associated loci, explore pathways en-
riched for nsCL/P associations and reveal tissues and cell types
where genes from associated loci are highly expressed. The
DEPICT framework relies on publicly available datasets and
uses large and diverse gene expression data, allowing annota-
tion of potential functional connections between genes at asso-
ciated loci. Here, we downloaded the beta version of DEPICT_v1
(http://www.broadinstitute.org/mpg/depict/; date last accessed
July 15, 2016) and performed the analysis in two settings: (i) all
autosomal SNPs with P < 51008 plus three top SNPs for each
of the known 24 loci that did not have genome-wide results in
our analyses (n¼816 SNPs); and (ii) all autosomal SNPs with
P < 51005 in the metaEuro data (n¼1470 SNPs). The latter set-
ting was chosen because limiting the analysis to known risk loci
only may result in loss of power because SNPs that have not yet
met appropriate thresholds of significance due to limited statis-
tical power. In each setting, gene prioritization, gene set enrich-
ment and tissue/cell type enrichment analyses respectively
were performed.
Supplementary Material
Supplementary Material is available at HMG online.
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